论文部分内容阅读
目的观察布地奈德雾化吸入治疗中重度慢性阻塞性肺疾病(COPD)急性加重期的疗效及安全性。方法选择65例COPD急性加重期患者,随机分为治疗组33例,对照组32例。在给予常规治疗的同时,治疗组雾化吸入布地奈德2mg.d-1,tid。对照组静脉点滴甲强龙40mg,qd。记录两组患者入院时及治疗后第1、3、5天的呼吸困难评分及肺功能、动脉血气分析及药物不良反应情况。结果两组患者治疗后呼吸困难评分及肺功能、动脉血气分析均明显改善。两组间比较无显著差异,治疗组不良反应发生率明显低于对照组。结论布地奈德雾化吸入治疗中重度COPD急性加重期的疗效与静脉点滴甲强龙相似,不良反应发生率低。可作为COPD急性加重期激素治疗的有效选择。
Objective To observe the efficacy and safety of inhaled budesonide in the treatment of acute exacerbation of moderate-severe chronic obstructive pulmonary disease (COPD). Methods Sixty-five patients with acute exacerbation of COPD were randomly divided into treatment group (n = 33) and control group (n = 32). At the same time as conventional treatment, the treatment group inhaled budesonide 2mg.d-1, tid. Control group intravenous methylprednisolone 40mg, qd. The scores of dyspnea, pulmonary function, arterial blood gas analysis and adverse drug reactions on the 1st, 3rd, 5th day after admission were recorded in both groups. Results After treatment, dyspnea score, pulmonary function and arterial blood gas analysis were significantly improved in both groups. No significant difference between the two groups, the incidence of adverse reactions in the treatment group was significantly lower than the control group. Conclusion The efficacy of budesonide inhalation in the treatment of moderate-severe acute exacerbation of COPD is similar to that of intravenous infusion of methylprednisolone, with a low incidence of adverse reactions. Can be used as an effective treatment of COPD acute exacerbation of hormone therapy.